中国医药指南
中國醫藥指南
중국의약지남
Guide of China Medicine
2015年
25期
12-13
,共2页
张文华%梁春辉%贾文玲%唐海涛%梁莹
張文華%樑春輝%賈文玲%唐海濤%樑瑩
장문화%량춘휘%가문령%당해도%량형
125I粒子组织间植入%肝动脉栓塞化疗%肝复乐片%原发性肝癌
125I粒子組織間植入%肝動脈栓塞化療%肝複樂片%原髮性肝癌
125I입자조직간식입%간동맥전새화료%간복악편%원발성간암
125I particle interstitial implant%Hepatic artery embolism chemotherapy%Ganfule tablet%Primary liver cancer
目的：研究125I粒子植入联合肝动脉栓塞化疗（TACE）及口服肝复乐片对原发性肝癌的治疗效果。方法回顾性分析116例确诊的原发性肝癌患者，A组37例（125I粒子植入联合TACE及肝复乐治疗组），B组36例（TACE联合肝复乐治疗组），C组43例（单纯TACE治疗组），3组均于治疗后第3、6、12个月行CT扫描进行疗效评价，分别比较3组治疗后6、12个月的生存状态。3组有效率及生存状态比较均采用卡方检验，以P＜0.05为差异有统计学意义。结果治疗3、6、12个月后，A组的有效率分别为78.4%、83.8%、24.3%，显著高于B组的44.4%、38.89%、8.3%和C组的39.5%、18.6%、4.6%，差异有统计学意义（P＜0.05）；治疗6、12个月后，A组生存率分别为89.2%和32.4%，明显高于B组的69.4%、16.7%和C组的46.5%、9.3%，差异有统计学意义（P＜0.05）。治疗6个月后， B组的有效率和生存率分别为38.89%、69.4%，明显高于C组的18.6%、46.5%，差异有统计学意义（P＜0.05）。结论 I125粒子植入联合TACE及肝复乐片是治疗肝癌的有效方法，具有良好的应用前景。
目的：研究125I粒子植入聯閤肝動脈栓塞化療（TACE）及口服肝複樂片對原髮性肝癌的治療效果。方法迴顧性分析116例確診的原髮性肝癌患者，A組37例（125I粒子植入聯閤TACE及肝複樂治療組），B組36例（TACE聯閤肝複樂治療組），C組43例（單純TACE治療組），3組均于治療後第3、6、12箇月行CT掃描進行療效評價，分彆比較3組治療後6、12箇月的生存狀態。3組有效率及生存狀態比較均採用卡方檢驗，以P＜0.05為差異有統計學意義。結果治療3、6、12箇月後，A組的有效率分彆為78.4%、83.8%、24.3%，顯著高于B組的44.4%、38.89%、8.3%和C組的39.5%、18.6%、4.6%，差異有統計學意義（P＜0.05）；治療6、12箇月後，A組生存率分彆為89.2%和32.4%，明顯高于B組的69.4%、16.7%和C組的46.5%、9.3%，差異有統計學意義（P＜0.05）。治療6箇月後， B組的有效率和生存率分彆為38.89%、69.4%，明顯高于C組的18.6%、46.5%，差異有統計學意義（P＜0.05）。結論 I125粒子植入聯閤TACE及肝複樂片是治療肝癌的有效方法，具有良好的應用前景。
목적：연구125I입자식입연합간동맥전새화료（TACE）급구복간복악편대원발성간암적치료효과。방법회고성분석116례학진적원발성간암환자，A조37례（125I입자식입연합TACE급간복악치료조），B조36례（TACE연합간복악치료조），C조43례（단순TACE치료조），3조균우치료후제3、6、12개월행CT소묘진행료효평개，분별비교3조치료후6、12개월적생존상태。3조유효솔급생존상태비교균채용잡방검험，이P＜0.05위차이유통계학의의。결과치료3、6、12개월후，A조적유효솔분별위78.4%、83.8%、24.3%，현저고우B조적44.4%、38.89%、8.3%화C조적39.5%、18.6%、4.6%，차이유통계학의의（P＜0.05）；치료6、12개월후，A조생존솔분별위89.2%화32.4%，명현고우B조적69.4%、16.7%화C조적46.5%、9.3%，차이유통계학의의（P＜0.05）。치료6개월후， B조적유효솔화생존솔분별위38.89%、69.4%，명현고우C조적18.6%、46.5%，차이유통계학의의（P＜0.05）。결론 I125입자식입연합TACE급간복악편시치료간암적유효방법，구유량호적응용전경。
Objective To investigate the treatment effect of125I particles implantation combined TACE and Ganfule treat primary liver cancer.Methods Retrospective analysis of 116 cases of patients which was diagnosed with primary liver cancer, A group had 37 cases(125I particles implantation combined TACE and Ganfule treatment group), B group had 36 cases(TACE and Ganfule treatment group), C group had 36 cases(only TACE treatment group), three groups were CT scan and curative effect evaluation after 3, 6, 12 months treatment, three groups were compared living condition after treatment for 6 months and 12 months. The efifcient and living condition of three groups of comparison adopt chi-square test,P<0.05 was statistically signiifcant.Results After 3, 6, 12 months treatment, the efifcient of group A respectively was 78.4%, 83.8% and 24.3%, signiifcantly higher than group B which was 44.4%, 38.89%, 8.3%, and higher than group C which was 39.5%, 18.6% and 4.6%, the difference was statistically signiifcant(P< 0.05). After 6 and 12 months treatment, the survival rates of group A respectively was 89.2% and 32.4% signiifcantly higher than group B which was 69.4%, 16.7%, and higher than group C which was 46.5%, 9.3%. The difference was statistically signiifcant(P<0.05). After 6 months treatment, the efifcient rates and survival rates of group B respectively were 38.89% and 16.7% signiifcantly higher than group C which was 18.6%, 46.5%, the difference was statistically signiifcant(P<0.05).Conclusion125I particles implantation combined TACE and Ganfule tablet is an effective method for treatment of liver cancer, has a good application prospect.
